AmikacinAmikacin
MedChemExpress (MCE)
HY-B0509A
37517-28-5
BAY 41-6551
99.93%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies.
Amikacin (30 µg, 0-24 h) has antibacterial activity, with a MIC50 value of 512 µg/mL against clinically isolated E. coli, and has a synergistic effect with imipenem (HY-B1369A), and the antibacterial effect is better when used in combination[1]. Amikacin (250 µg/mL, 0-24 h) inhibits the migration and invasion of human breast cancer cell line MDA-MB-231 cells by up-regulating the expression of TXNIP, indicating its anti-tumor potential[2].
Amikacin (single 30 mg/kg, s.c. or i.p.) has an analgesic effect in mice and has a synergistic effect when combined with morphine, but the analgesic effect of Amikacin can be reversed by Naloxone (HY-17417A)[3]. Amikacin (500 mg/kg/day for 8 days, s.c.) damages calpain activity in rat cochlea, promotes the degradation of sensory cells and neurons, and then leads to ototoxicity[4]. Amikacin (100 and 500 mg/kg/day for 10 days, s.c.) is nephrotoxic and its continued accumulation in rats can lead to kidney damage[5]. Pharmacokinetic Analysis in SD rats[5] Route Dose (mg/kg) Ka (h-1) Ke1 (h-1) t1/2 (h) V (liter/kg) AUC0-∞ (mg·h/mL) s.c. 100 1.20 6.77 0.10 0.28 53.0 s.c. 500 1.40 1.39 0.50 0.55 649.7
Aminoglycoside TXNIP
| | | |
| | | | | |
[1]. Farhan SM, et al. In Vitro and In Vivo Effect of Amikacin and Imipenem Combinations against Multidrug-Resistant E. coli. Trop Med Infect Dis. 2022 Oct 2
7(10):281. [Content Brief]
[2]. Wang YH, et al. Amikacin Suppresses Human Breast Cancer Cell MDA-MB-231 Migration and Invasion. Toxics. 2020 Nov 20
8(4):108. [Content Brief]
[3]. Atamer-Simsek S, et al. Antinociceptive effect of amikacin and its interaction with morphine and naloxone. Pharmacol Res. 2000 Mar
41(3):355-60. [Content Brief]
[4]. Ladrech S, et al. Calpain activity in the amikacin-damaged rat cochlea. J Comp Neurol. 2004 Sep 13
477(2):149-60. [Content Brief]
[5]. Chan K, et al. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 Aug 20
64(9):e00859-20. [Content Brief]